RPRX · ISSUER CIK 1802768
Royalty Pharma plc
Between Aug 1, 2026 and Oct 29, 2026, 5 Royalty Pharma plc insiders reported $0.00 of open-market purchases and $13.0M of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 5 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$13.0MInsider selling
−$13.0MNet open-market
Oct 5, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 202617:12 | Oct 5, 2026 | RPRX | EVP, Research & Investments | S · Sell10b5-1 | $57.10 | −4,126 | 0 | -100% | −$236K | ||
| Sep 30, 202616:33 | Sep 30, 2026 | RPRX | Director | A · Grant | $58.41 | +642 | 79,823 | +1% | $37K | ||
| Sep 30, 202616:32 | Sep 28, 2026 | RPRX | EVP, Research & Investments | S · Sell10b5-1 | $57.88 | −4,126 | 4,126 | -50% | −$239K | ||
| Sep 24, 202616:10 | Sep 22, 2026 | RPRX | EVP & Chairman, Partnering | S · Sell10b5-1 | $58.53 | −100,000 | 270,401 | -27% | −$5.9M | ||
| Aug 19, 202616:20 | Aug 18, 2026 | RPRX | EVP & Chairman, Partnering | S · Sell10b5-1 | $59.97 | −100,000 | 370,401 | -21% | −$6.0M | ||
| Aug 19, 202616:20 | Aug 19, 2026 | RPRX | EVP & Chairman, Partnering | G · Gift10b5-1 | — | −16,800 | 23,200 | -42% | — | ||
| Aug 17, 202617:01 | Aug 13, 2026 | RPRX | EVP & CFO | S · Sell10b5-1 | $58.68 | −11,002 | 0 | -100% | −$646K | ||
| Aug 7, 202617:24 | Aug 5, 2026 | RPRX | CEO, Chairman of the Board, Director | A · Grant | — | +65,216 | 1,307,820 | +5% | — | ||
| Aug 7, 202617:24 | Aug 5, 2026 | RPRX | EVP & CFO | A · Grant | — | +11,002 | 11,002 | New | — | ||
| Aug 7, 202617:12 | Aug 5, 2026 | RPRX | EVP & Chairman, Partnering | A · Grant | — | +11,002 | 470,401 | +2% | — | ||
| Aug 7, 202617:11 | Aug 5, 2026 | RPRX | EVP, Research & Investments | A · Grant | — | +8,252 | 8,252 | New | — |